But high medical costs contributed to results that disappointed Wall Street, and the company’s stock fell on the news that it had made less than analysts expected.
Related Posts
F.D.A. Delays Action on Closely Watched Alzheimer’s Drug
Eli Lilly’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of…
Nursing Home Industry Wants Trump to Rescind Staffing Mandate
A Biden administration rule that imposed minimum rules on nursing levels may not survive, even though many homes lack enough…
Seizures of Psychedelic Mushrooms Rise in U.S. as Demand Grows
Seizures of psychedelic mushrooms across the nation by law enforcement officials have increased significantly in recent years as attitudes regarding…